Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Medicine|December 29, 2021
Anticoagulation treatment for patients with coronavirus disease 2019 (COVID-19) and its clinical effectiveness in 2020: A meta-analysis studyJingyi Ge, Yingmin Ma, Zhipeng Wu, et al.
Infection and Drug Resistance|November 25, 2024
Positive HIV Screening Test in a Patient with Rapidly Progressive Interstitial Lung Disease: A Case ReportXue Chen, Miaotian Cai, Yingmin Ma, et al.
BMC Pulmonary Medicine|June 4, 2024
Serum S1P level in interstitial lung disease (ILD) is a potential biomarker reflecting the severity of pulmonary functionFangping Ding, Zhenyang Wang, Jing Wang, et al.
Iranian Journal of Biotechnology|July 20, 2026
Screening of Biomarkers Related to Mitophagy in Severe Pancreatitis Based on Bioinformatics MethodsJiajia Li, Jinxin Cao, Zhipeng Wu, et al.
Annals of Translational Medicine|May 9, 2022
A combination of the APACHE II score, neutrophil/lymphocyte ratio, and expired tidal volume could predict non-invasive ventilation failure in pneumonia-induced mild to moderate acute respiratory distress syndrome patientsWei Sun, Zujin Luo, Zhixin Cao, et al.
Clinical Laboratory|December 9, 2015
Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During ChemotherapyQian Wang, Lei Yang, Feng Xu, et al.
Frontiers in Pediatrics|October 31, 2025
Assessment on the incidence of notifiable infectious diseases in pediatrics post-COVID-19: a retrospective study based on data from 2020 to 2023Wei Sun, Zujin Luo, Shunli Li, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 10, 2022
Fibrinogen, a Promising Marker to Evaluate Severity and Prognosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Observational StudyWei Sun, Zhixin Cao, Yingmin Ma, et al.
Frontiers in Immunology|May 20, 2022
The Levels of Oxidized Phospholipids in High-Density Lipoprotein During the Course of Sepsis and Their Prognostic ValueZhaohong Li, Zengtao Luo, Xiaoqian Shi, et al.
Clinical Laboratory|July 13, 2012
The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell linesYanwen Jiang, Chunsun Li, Yingmin Ma, et al.
Pageof 9